Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Wang, Jiani ^a   Xu, Lihua ^b   Zeng, Weigen ^a,c   Hu, Pan ^a   Zeng, Musheng ^d   Rabkin, Samuel D ^e   Liu, Renbin ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c CANCER HOSPITAL   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cytotoxicity; Hepatocellular carcinoma; Oncolytic herpes simplex virus; Subcutaneous model

Indexed keywords

BETA GALACTOSIDASE; ONCOLYTIC HERPES SIMPLEX VIRUS G47 DELTA; ONCOLYTIC HERPES VIRUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BALB/C NUDE MOUSE; BEL 7404 CELL LINE; BEL 7405 CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; HEP3B CELL LINE; HEPATOCELLULAR CARCINOMA CELL LINE; HEPG2 CELL LINE; HISTOCHEMISTRY; HL 7702 CELL LINE; HUMAN; HUMAN CELL; IMMORTALIZED CELL LINE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SMMC 7721 CELL LINE; SURVIVAL TIME; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME; VIRUS REPLICATION; X GAL STAINING;

EID: 84988666949     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/s12935-014-0083-y     Document Type: Article

References (42)

1. Jain S, Singhal S, Lee P, Xu R: Molecular genetics of hepatocellular neoplasia. Am J Transl Res 2010, 2(1):105-118.
2. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108.
3. Paul SB, Manjunatha YC, Acharya SK: Palliative treatment in advanced hepatocellular carcinoma: has it made any difference? Trop Gastroenterol 2009, 30(3):125-134.
4. Padma S, Martinie JB, Iannitti DA: Liver tumor ablation: percutaneous and open approaches. J Surg Oncol 2009, 100(8):619-634.
5. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA: Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002, 963:13-20.
6. Block TM, Mehta AS, Fimmel CJ, Jordan R: Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003, 22(33):5093-5107.
7. Marrero JA: Hepatocellular carcinoma. Curr Opin Gastroenterol 2006, 22(3):248-253.
8. Oyagbemi AA, Azeez OI, Saba AB: Hepatocellular carcinoma and the underlying mechanisms. Afr Health Sci 2010, 10(1):93-98.
9. Arzumanyan A, Reis HM, Feitelson MA: Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013, 13(2):123-135.
10. Nebbia G, Peppa D, Maini MK: Hepatitis B infection: current concepts and future challenges. QJM 2012, 105(2):109-113.
11. Sarbah SA, Gramlich T, Younoszai A, Osmack P, Goormastic M, Grosso L, Cooper JN, Di Bisceglie A, Seneca R, Younossi ZM: Risk factors for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci 2004, 49(5):850-853.
12. Barraud H, Bronowicki JP: [Curative treatment of hepatocellular carcinoma]. Rev Prat 2013, 63(2):229-233.
13. Llovet JM: Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005, 40(3):225-235.
14. Simillis C, Constantinides VA, Tekkis PP, Darzi A, Lovegrove R, Jiao L, Antoniou A: Laparoscopic versus open hepatic resections for benign and malignant neoplasms-a meta-analysis. Surgery 2007, 141(2):203-211.
15. Schemmer P, Friess H, Hinz U, Mehrabi A, Kraus TW, Z'Graggen K, Schmidt J, Uhl W, Buchler MW: Stapler hepatectomy is a safe dissection technique: analysis of 300 patients. World J Surg 2006, 30(3):419-430.
16. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M: Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001, 48(2):251-259.
17. Wong J, Lee C, Zhang K, Rennie PS, Jia W: Targeted oncolytic herpes simplex viruses for aggressive cancer. Curr Pharm Biotechnol 2012, 13(9):1786-1794.
18. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991, 252(5007):854-856.
19. Varghese S, Rabkin SD: Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002, 9(12):967-978.
20. Bennett JJ, Delman KA, Burt BM, Mariotti A, Malhotra S, Zager J, Petrowsky H, Mastorides S, Federoff H, Fong Y: Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther 2002, 9(11):935-945.
21. McAuliffe PF, Jarnagin WR, Johnson P, Delman KA, Federoff H, Fong Y: Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J Gastrointest Surg 2000, 4(6):580-588.
22. Delman KA, Bennett JJ, Zager JS, Burt BM, McAuliffe PF, Petrowsky H, Kooby DA, Hawkins WG, Horsburgh BC, Johnson P, Fong Y: Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther 2000, 11(18):2465-2472.
23. Cozzi PJ, Burke PB, Bhargav A, Heston WD, Huryk B, Scardino PT, Fong Y: Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate 2002, 53(2):95-100.
24. Cozzi PJ, Malhotra S, McAuliffe P, Kooby DA, Federoff HJ, Huryk B, Johnson P, Scardino PT, Heston WD, Fong Y: Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J 2001, 15(7):1306-1308.
25. Shen Y, Nemunaitis J: Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther 2006, 13(11):975-992.
26. Liu S, Dai M, You L, Zhao Y: Advance in herpes simplex viruses for cancer therapy. Sci China Life Sci 2013, 56(4):298-305.
27. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000, 7(10):867-874.
28. Poortmans PM, Ataman F, Davis JB, Bartelink H, Horiot JC, Pierart M, Collette L, Van Tienhoven G: Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual period. Adiother Oncol 2005, 76(3):278-284.
29. Russell SJ, Peng KW, Bell JC: Oncolytic virotherapy. Nat Biotechnol 2012, 30(7):658-670.
30. Todo T, Martuza RL, Rabkin SD, Johnson PA: Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 2001, 98(11):6396-6401.
31. Chou J, Kern ER, Whitley RJ, Roizman B: Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990, 250(4985):1262-1266.
32. Markert JM, Malick A, Coen DM, Martuza RL: Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993, 32(4):597-603.
33. Chambers R, Gillespie GY, Soroceanu L, Andreansky S, Chatterjee S, Chou J, Roizman B, Whitley RJ: Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci U S A 1995, 92(5):1411-1415.
34. Mohr I, Gluzman Y: A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J 1996, 15(17):4759-4766.
35. Goldstein DJ, Weller SK: Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988, 62(1):196-205.
36. Carroll NM, Chiocca EA, Takahashi K, Tanabe KK: Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 1996, 224(3):323-329. discussion 329-330.
37. Mineta T, Rabkin SD, Martuza RL: Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994, 54(15):3963-3966.
38. Toda M, Rabkin SD, Kojima H, Martuza RL: Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999, 10(3):385-393.
39. Thomas DL, Fraser NW: HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer. Mol Ther 2003, 8(4):543-551.
40. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, Love CA, Coffin RS: ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003, 10(4):292-303.
41. York IA, Roop C, Andrews DW, Riddell SR, Graham FL, Johnson DC: A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 1994, 77(4):525-535.
42. Farassati F, Pan W, Yamoutpour F, Henke S, Piedra M, Frahm S, Al-Tawil S, Mangrum WI, Parada LF, Rabkin SD, Martuza RL, Kurtz A: Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am J Pathol 2008, 173(6):1861-1872.